Cathay International Holdings Ld Total Voting Rights (0470O)
30 September 2019 - 4:02PM
UK Regulatory
TIDMCTI
RNS Number : 0470O
Cathay International Holdings Ld
30 September 2019
30 September 2019
Dissemination of a Regulatory Announcement that contains inside
information according to REGULATION (EU) No 596/2014 (MAR).
Cathay International Holdings Limited
Total Voting Rights
In conformity with Rule 5.6.1 of the Disclosure Guidance and
Transparency Rules, we notify the market that as at 30 September
2019 Cathay International Holdings Limited's capital consisted of
372,289,515 common shares of USD 0.5 each ("Common Shares") and
8,953,259 A shares of USD 0.5 each ("A Shares"), of which 3,200,000
Common Shares are held in Treasury.
The A Shares and the Common Shares rank equally in all respects
save that each A Share carries 20 votes and each Common Share
carries one vote. A Shares are convertible into Common Shares on a
one for one basis in accordance with the Bye-Laws of the
Company.
Only the Common Shares are admitted to trading.
Accordingly, the total number of voting rights attached to the
Common Shares is 369,089,515 and this figure should be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, Cathay International Holdings
Limited under the Disclosure Guidance and Transparency Rules.
-Ends-
For further enquiries, please contact:
Cathay International Holdings Limited
Eric Siu (Finance Director) Tel: +852 2828 9289
Patrick Sung (Director and Controller)
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal / Tel: +44 (0) 203 709 5702
Lindsey Neville
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the healthcare sector in the People's Republic of China
(the "PRC"). The Company and its subsidiaries (collectively the
"Group") aim to leverage on investment opportunities in the growing
domestic demand for high quality healthcare products in the PRC and
build portfolio companies into market sector leaders with
competitive edge. Cathay has already demonstrated a track record of
identifying investment opportunities in this area including:
Lansen, a leading specialty pharmaceutical company focused on
rheumatology and dermatology in the PRC; Haizi, a company engaged
in the manufacture, marketing and sale of inositol and its
by-product, di-calcium phosphate; Natural Dailyhealth, a company
engaged in production and sales of plant extracts for use as key
active ingredients in healthcare products; and Botai, a company
engaged in collagen products.
The Group employs approximately 1,500 people across the PRC,
including over 20 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment. For more information
please visit the Company's website: www.cathay-intl.com.hk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRBIGDCUSDBGCC
(END) Dow Jones Newswires
September 30, 2019 02:02 ET (06:02 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024